LAT CAB (2021-present)

The LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, HIV, and latent TB infection.

Materials in this section


LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, HIV, and LTBI. More

CABsLAT CAB (2021-present)